CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies. Issue 1 (2nd January 2022)

• Record Type: Journal Article
• Authors: Wilson, Nathaniel R.; Bover, Laura; Konopleva, Marina; Han, Lina; Neelapu, Sattva; Pemmaraju, Naveen
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 1(2022)
• Page Start: 19
• Page End: 30
• Publication Date: 2022-01-02
• Subjects: CD303 -- BDCA-2 -- BPDCN -- pDC-AML -- targeted therapy -- monoclonal antibody; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1975192
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Plasmacytoid dendritic cells (pDCs) serve as immunoregulatory antigen-presenting cells that play a role in various inflammatory, viral, and malignant conditions. Malignant proliferation of pDCs is implicated in the pathogenesis of certain hematologic cancers, specifically blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myelogenous leukemia with clonal expansion of pDC (pDC-AML). In recent years, BPDCN and pDC-AML have been successfully treated with targeted therapy of pDC-specific surface marker, CD123. However, relapsed and refractory BPDCN remains an elusive cancer, with limited therapeutic options. CD303 is another specific surface marker of human pDCs, centrally involved in antigen presentation and immune tolerance. Monoclonal antibodies directed against CD303 have been studied in preclinical models and have achieved disease control in patients with cutaneous lupus erythematosus. We performed a comprehensive review of benign and malignant disorders in which CD303 have been studied, as there may be a potential future CD303-directed therapy for many of these conditions.